Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancer

• DOI: 10.1002/cncr.21872
• Publication Date: 2006-04-06T13:28:47Z
• Authors: Luigi Cataliotti; Aman U. Buzdar; Shinzaburo Noguchi; Jose Bines; Yuichi Takatsuka; Katarina Petrakova; Pierre Dube; Celia Tosello de ...
• Keywords: Anastrozole; Antiestrogen; Hormonal Therapy

The Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) study was a randomized, multicenter comparing anastrozole with tamoxifen as preoperative treatment of postmenopausal women large, operable (T2/3, N0-2, M0), or potentially (T4b, M0) breast cancer. effect endocrine therapy in patients scheduled for mastectomy inoperable tumors at baseline also investigated.Patients hormone receptor-positive cancer received (n = 228) 223) without chemotherapy 12 weeks before primary surgery.Objective responses and occurred 39.5% 35.4% patients, respectively (ultrasound measurements), 50.0% 46.2% (caliper measurements). In hormonal therapy-only 314), feasible surgery improved after 3 months 43.0% receiving 30.8% (P .04). the intent-to-treat population, improvement actual found be numerically higher group compared group, although this difference did not reach significance. Drug-related adverse events were reported 20.2% 18.1% respectively, groups.Anastrozole is an effective well-tolerated therapy, producing clinically beneficial tumor downstaging reductions volume. These effects enable more minimal surgical interventions mastectomy, previously tumors. Anastrozole appears least setting, than certain relevant subgroups. Cancer 2006. (c) 2006 American Society.